1693P Incidence of NTRK genes fusion in adult brain tumours: A prospective cohort of 140 patients with cerebral gliomas and brain metastases

Abstract

Oncogenic fusion of neurotrophin receptor tyrosine kinase NTRK1, NTRK2, or NTRK3 genes have been found in different types of solid tumours. Nevertheless, the incidence of NTRK gene fusions in these cancers remains quite unexplored. The treatment of patients with TRK fusion cancer with a first-generation TRK inhibitor (such as larotrectinib or entrectinib) is associated with high response rates (>75%), regardless of tumour histology and presence of metastases, and acceptable toxicity profile. Due to the efficacy of TRK inhibitor therapy and the recent Food and Drug Administration and European Medicines Agency approval of larotrectinib and entrectinib, it is clinically important to identify patients accurately and efficiently with TRK fusion cancer.